### Project Title
Optimizing PD-L1 testing practices in our region

### Problem/Challenge
There is a need to provide PD-L1 testing in a timely, coordinated fashion so that treatment decisions are not delayed.

### Aim/Goal
Engage community pathology groups in our region through education and structured discussions around optimal PD-L1 testing practices. Establish ongoing dialogue around ways to improve PD-L1 testing.

### Key Interventions
We began by reviewing how our PD-L1 testing processes had evolved in our own lab. We brought PD-L1 testing in-house and focused our efforts on PD-L1 testing for patients diagnosed with NSCLC. We wanted to share our experience with other pathology groups in our region (Northern California Sutter Health), so scheduled a series of meetings to discuss how other pathology groups were coordinating PD-L1 testing. We outlined how PD-L1 testing can be incorporated into reflex testing protocols for NSCLC and how to handle small tissue samples so that enough remains for biomarker testing. We discussed perspectives around the pros/cons of in-house PD-L1 testing, the issues around different interpretation methods (eg, tumor proportion score vs. combined positive score), and the latest guideline recommendations based on expanding FDA approvals and indications for checkpoint inhibitors.

### Summary of Results
We held several meetings with other pathology groups in our region in 2021 and discussed some of the practical challenges around PD-L1 testing. We also shared our processes around reflex PD-L1 testing in NSCLC and on how to handle and process needle biopsy samples to improve our ability to perform biomarker testing with these small samples.

### Project Team/Affiliation
Mamatha Chivukula, MD, FASCP, FCAP
Mills-Peninsula Medical Center Sutter Health